|
Jenex Regulatory Update
Jenex Regulatory Update
FOR IMMEDIATE RELEASE
June 28, 2002
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), Michael Jenkins, President and CEO of Jenex announces the Corporation has received a response from FDA on their application to gain marketing clearance in the United States for their cold sore prevention device. Clearance was not granted at this time and the FDA recommended a teleconference for further discussion. The teleconference included FDA officials, senior management of Jenex and their professional, medical and clinical advisors. During the teleconference it was determined the FDA required additional clinical information in order to grant clearance to market. The protocol to be followed for the submission of clinical data was also determined. Subsequent to the teleconference, management and their FDA advisors have developed their plan of action and are confident they will successfully complete and submit the required data within a reasonable time frame.
The Corporation, while working on clearance to market in the USA, will pursue a qualified consumer products and/or pharmaceutical company to license their technology and market their cold sore prevention device for the Canadian market. Jenex has clearance to market their cold sore device in Canada with the claim “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”.
“Prevention is the Solution”
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release.
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario, L7L 5K6
Michael A. Jenkins, President
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@sprint.ca
Website: www.jenexcorp.com
|
